Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synflorix Co-administration with DTPa-IPV-Hib vs DTPa-HBV-IPV/Hib in Infants
NCT00652951Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2008
- Primary completion
- May 2009
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of 10-valent pneumococcal conjugate vaccine in pneumococcal infection and Haemophilus influenzae infection (3 arms), sponsored by GSK. Primary endpoints: Antibody Concentrations Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F at Month 3 and Antibody Concentration Against Protein D (PD) at Month 3. Started Apr 2008; status: completed.
02
Drugs
10-valent pneumococcal conjugate vaccine
03
Conditions
pneumococcal infectionHaemophilus influenzae infection
Beyond the preview
Go deeper on NCT00652951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00652951.